Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $57.3M | $63.4M | $61.3M | $62.2M | $61.9M | $72.8M | $83.6M | $101M | $69.3M |
| Revenue growth | — | — | 10.6% | -3.3% | 1.5% | -0.4% | 17.6% | 14.8% | 21.4% | -31.8% |
| Gross profit | $6.75M | $3.70M | -$1.58M | $2.84M | $2.73M | -$2.42M | $4.08M | $8.70M | $17.5M | $11.7M |
| Gross margin | — | 6.5% | -2.5% | 4.6% | 4.4% | -3.9% | 5.6% | 10.4% | 17.2% | 16.9% |
| Operating income | -$20.2M | -$25.9M | -$32.4M | -$34.5M | -$28.4M | -$30.3M | -$16.8M | -$6.67M | $608K | -$4.69M |
| Operating margin | — | -45.2% | -51.2% | -56.3% | -45.7% | -49.0% | -23.0% | -8.0% | 0.6% | -6.8% |
| Net income | -$19.8M | -$25.9M | -$32.1M | -$34.1M | -$30.9M | -$32.7M | -$18.7M | -$8.44M | -$480K | -$5.31M |
| Net margin | — | -45.2% | -50.7% | -55.7% | -49.7% | -52.8% | -25.7% | -10.1% | -0.5% | -7.7% |
| EPS (diluted) | -$0.39 | -$0.51 | -$0.61 | -$0.56 | -$0.41 | -$3.83 | -$1.31 | -$0.37 | -$0.03 | -$0.15 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.5M | -$21.1M | -$20.4M | -$27.3M | -$29.6M | -$33.5M | -$16.9M | -$9.41M | $4.20M | -$659K |
| Capital expenditures | — | — | — | — | — | — | — | $284K | $1.01M | $542K |
| Free cash flow | — | — | — | — | — | — | — | -$9.70M | $3.19M | -$1.20M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $17.2M | $8.41M | $22.7M | $11.8M | $48.7M | $13.3M | $10.1M | $8.98M | $15.7M | $10.7M |
| Total assets | $83.2M | $58.8M | $52.6M | $44.3M | $77.7M | $48.6M | $46.6M | $52.2M | $59.2M | $57.1M |
| Total liabilities | — | $25.9M | $25.3M | $24.0M | $43.6M | $46.0M | $32.5M | $30.9M | $26.6M | $20.2M |
| Long-term debt | — | — | — | $0.00 | $20.9M | $13.2M | $7.55M | $8.29M | $8.47M | $8.83M |
| Shareholders' equity | $53.0M | $32.9M | $27.3M | $20.3M | $34.2M | $2.54M | $14.1M | $21.3M | $32.6M | $37.0M |
| Retained earnings | -$214M | -$240M | -$272M | -$307M | -$337M | -$370M | -$389M | -$397M | -$398M | -$403M |
| Shares (wtd avg diluted) | 50.7M | 51.1M | 57.0M | 65.4M | 75.6M | 8.53M | 14.3M | 23.3M | 31.1M | 36.0M |
Every figure is extracted from ROCKWELL MEDICAL, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.